Total RadIoTherapy of Oligometastatic caNcerS

Inclusion Criteria

• •1. Provision of signed and dated informed consent form.
• •2. Stated willingness to comply with all study procedures and availability for the duration of the study.
• •3. Age at least 18 years.
• •4. Deemed eligible to undergo standard systemic therapy and SABR to metastatic sites (i.e., patient has adequate health and life expectancy, and treatment is not contraindicated).
• •5. Histopathologic confirmation of a solid malignancy.
• •6. Newly diagnosed or progressive metastasis (at least 1 and no more than 10 discrete distant metastases visible on staging imaging. At least one metastatic lesion must be outside the brain parenchyma) for which a new line of systemic therapy is started or resumed.
• •7. New systemic therapy for metastatic disease initiated no more than 6 months prior to randomization.
• •8. For participants able to become pregnant: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during active SABR treatment.
• •9. For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner during active SABR treatment.